Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

• Príomhchruthaitheoirí: Li Y (Údar), Lu JJ (Údar), Zhong XY (Údar), Yu YY (Údar), Yu N (Údar), Wang Y (Údar), Yi XM (Údar), Ding YF (Údar), Shi YL (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Dove Medical Press, 2022-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Ying Li1,2 *, Jia-Jing Lu1,2 *, Xiao-Yuan Zhong1,2 *, Ying-Yuan Yu1,2 *, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People's...